ReviewFrontiers in oncology2024
A comprehensive review of current knowledge on penile squamous cell carcinoma.
Review in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Organ-sparing radiotherapy in penile cancer: therapeutic approaches.International urology and nephrology · 2026Pooled it
- Article
- Article
- Pathway from lichen sclerosus to squamous cell carcinoma of the penis: the oncologist's perspective.Urology case reports · 2026Article
- Genital basal cell carcinoma in sun-protected sites: sex-stratified clinicopathologic features, p16/HPV status, and long-term outcomes in an Asian cohort.Frontiers in medicine · 2026Article
- Comprehensive review of penile cancer using MR imaging.Insights into imaging · 2025Article
- Demographics, Clinical Characteristics, and a Stage-Based Analysis of Treatments and Outcomes for Squamous Cell Carcinoma of the Penis.Cancer reports (Hoboken, N.J.) · 2025Article
- Magnetic sentinel node biopsy with Sienna+®/SentiMag® in penile squamous cell carcinoma: Case report.Urology case reports · 2025Article
- Smoking and presence of human papillomavirus correlates with lymphocyte density in the stroma of penile squamous cell carcinoma.Frontiers in oncology · 2025Article
- Exploring the Multifactorial Landscape of Penile Cancer: A Comprehensive Analysis of Risk Factors.Diagnostics (Basel, Switzerland) · 2024Review
- The ulcer that deceived: Squamous cell carcinoma masquerading as a primary chancre.Indian journal of sexually transmitted diseases and AIDSArticle
- Penile Carcinoma Presented with Ilioinguinal Lymphadenopathy, Below-knee Skeletal Metastases, and Peritoneal Superscan onIndian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, IndiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neoplasm of the penis is relatively rare in most regions representing 0-2% of cancers worldwide. While the penis can be affected by sarcomas, basal cell carcinomas or even melanoma, Penile Squamous Cell Carcinoma (PSCC) represents approximately 95% of all penile neoplasms. Despite its rarity and most common presentation at later decades of life most individuals diagnosed with PSCC are faced with significant decrease in quality of life. The prevalence and incidence vary among different regions and populations, but a common trend is for diagnosis to occur late (stage 4). Underdeveloped countries are traditionally reported to have higher incidence rates; however, rates may vary significantly between urban and rural areas even in developed countries. Age adjusted rates are on the rise in some countries that used to have incidence rates of 1:100 000 or less. The list of associated risk factors is long and includes among others, lack of neonatal circumcision, poor genital hygiene, socioeconomic status, history of human papillomavirus (HPV) infection and penile intraepithelial neoplasia (PeIN). Many risk factors are widely debated among experts however HPV and PeIN are indisputable risk factors, and both also form part of the classification system for PSCC. Both conditions may have occurred in the past or be present at the time of diagnosis and identifying them plays a major role in management strategies. For such a rare condition PSCC can present in many different forms clinically making diagnosis no easy feat. Diagnosis of PSCC is done through clinical examination, including lymph node palpation, followed by a biopsy, which is essential for the classification. Lymph node involvement is a common finding at first presentation and investigation of spread to deep nodes is important and can be done with the aid of PET-CT. Treatment options for PSCC include surgery, chemotherapy, and radiation therapy. Surgical removal of the tumor is considered the most effective however can lead to severe decrease of quality of life. Chemotherapy is used in the case of fixed or bulky lymph nodes, where surgery is not indicated, and for distant metastasis. Radiation therapy is particularly effective in the case of HPV-positive PSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.